Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
暂无分享,去创建一个
A. Chen | D. Gandara | M. Goetz | J. Sparano | R. Nanda | B. Arun | Cynthia X Ma | T. Moynihan | P. Frankel | H. Chew | J. Weitzel | G. Somlo | J. Mortimer | L. Vahdat | A. Hurria | H. Harvey | Cynthia X. Ma | T. Luu | Agustin A. Garcia | L. Cream | T. Cigler